San Francisco, CA1 Active Studies

Restless Legs Syndrome Clinical Trials in San Francisco, CA

Find 1 actively recruiting restless legs syndrome clinical trials in San Francisco, CA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
50
Enrolling

Recruiting Restless Legs Syndrome Studies in San Francisco

About Restless Legs Syndrome Clinical Trials in San Francisco

Restless legs syndrome (RLS) is a neurological condition characterized by an uncontrollable urge to move the legs, usually accompanied by uncomfortable sensations. Symptoms typically worsen at night and can severely disrupt sleep. Treatment includes iron supplementation, dopaminergic agents, and lifestyle modifications.

There are currently 1 restless legs syndrome clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 50 participants. Research is being sponsored by HBC Immunology Inc. Clinical trial participation is free and participants receive study-related medical care at no cost.

Restless Legs Syndrome Clinical Trials in San Francisco — FAQ

Are there restless legs syndrome clinical trials in San Francisco?

Yes, there are 1 restless legs syndrome clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What restless legs syndrome treatments are being tested?

The 1 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for restless legs syndrome.

Data updated July 17, 2026 from ClinicalTrials.gov